Novavax Stock News

(PR-inside.com) SAN FRANCISCO, CA / ACCESSWIRE / November 19, 2021 / Hagens Berman urges Novavax, Inc. (NASDAQ:NVAX) investors with significant losses to submit your losses now. Class Period: Mar. 2, 2021 - Oct. 19, 2021 Lead Plaintiff Deadline: Jan. 11, 2022 Visit: www.hbsslaw.com/investor-fraud/NVAX Contact An Attorney Now: [email protected] 844-916-0895 Novavax, Inc. (NVAX) Securities Fraud Class Action: The lawsuit alleges that Defendants misrepresented Novavax''s progress toward successfully developing its COVID-19 vaccine (NVX-CoV2373), including: (1) overstating Novavax''s manufacturing capabilities and downplaying manufacturing issues that would impact the approval timeline for NVX-CoV2373; (2) concealing that Novavax was unlikely to meet its anticipated EUA regulatory timelines; (3) exaggerating the regulatory and commercial ..

NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than January 18, 2022 in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Novavax, Inc. (Novavax) (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021, inclusive (the Class Period). The lawsuit was filed in the United States District Court for the District of Maryland and alleges violations of the Securities Exchange Act of 1934.

(PR-inside.com) BOSTON, MA / ACCESSWIRE / November 19, 2021 / The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Novavax, Inc. (NASDAQ:NVAX). The case is currently in the lead plaintiff stage. Investors who purchased NVAX securities between March 2, 2021 and October 19, 2021 may contact the Thornton Law Firm''s investor protection team by visiting www.tenlaw.com/cases/Novavax for more information. Investors may also email [email protected] or call 617-531-3917. FOR MORE INFORMATION: www.tenlaw.com/cases/Novavax The case alleges that Novavax and its senior executives made misleading statements to investors and failed to disclose that: (i) Novavax overstated ..

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming January 11, 2022 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Novavax, Inc. (Novavax or the Company) (NASDAQ: NVAX) securities between March 2, 2021 and October 19, 2021, inclusive (the Class Period). Investors suffering losses on their Novavax investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal righ

Novavax Inc. (NASDAQ:NVAX)s traded shares stood at 4.22 million during the last session, with the companys beta value hitting 1.33. At the close of trading, the stocks price was $191.05, to imply an increase of 3.84% or $7.06 in intraday trading. The NVAX shares 52-week high remains $331.68, putting it -73.61% down since that peak Novavax Inc. (NASDAQ: NVAX) Is Currently -73.61 Percent Below Its 52-Week High, But It Still Offers Strong Upside Potential. Read More »

Wall Street analysts expect Novavax, Inc. (NASDAQ:NVAX) to post earnings of $0.36 per share for the current quarter, according to Zacks. Four analysts have made estimates for Novavaxs earnings, with estimates ranging from ($4.95) to $7.89. Novavax posted earnings per share of ($2.70) in the same quarter last year, which suggests a positive year-over-year growth []

(PR-inside.com) NEW YORK, NY / ACCESSWIRE / November 19, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you. Hoegh LNG Partners Lp (NYSE:HMLP) If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/hoegh-lng-partners-lp-loss-submission-form?prid=21398&wire=1Lead Plaintiff Deadline: December 27, 2021Class Period: August 22, 2019 - July 27, 2021 Allegations against HMLP include that: (1) the Partnership was facing issues with the PT ..

The European Unions drug regulator said it received an application from Novavax to authorize the American biotechnology companys coronavirus vaccine, a request that could significantly boost the continents vaccine supplies if its granted. In a statement yesterday [Macau time], the European Medicines Agency said it had begun evaluating data submitted by Novavax for its two-dose []

The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Novavax, Inc. (Novavax) (NASDAQ: NVAX). The action charges Novavax with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the companys business, operations, and prospects. As a result of Novavaxs

-- Novavax y Serum Institute of India reciben autorización de uso de emergencia para la vacuna COVID-19 en Filipinas GAITHERSBURG, Md. y PUNE, India, 18 de noviembre, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de

(PR-inside.com) NEW YORK, NY / ACCESSWIRE / November 18, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn''t require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below. Camber Energy, Inc. (NYSE:CEI) CONTACT JAKUBOWITZ ABOUT CEI:https://claimyourloss.com/securities/camber-energy-inc-loss-submission-form/?id=21372&from=1 Class Period: February 18, ..

Novavax, Inc. (NASDAQ:NVAX) shares gapped up prior to trading on Thursday . The stock had previously closed at $183.99, but opened at $194.08. Novavax shares last traded at $188.01, with a volume of 38,288 shares changing hands. A number of equities analysts recently commented on NVAX shares. Chardan Capital restated a neutral rating on shares []

The biotechnology company Novavax, Inc. (NVAX) has been in the headlines due to news related to its COVID-19 vaccine. The post Novavaxs COVID-19 Vaccine under EMAs Review for CMA; Shares Rise appeared first on Smarter Analyst .

Beset by delays, this vaccine is becoming available when low-income countries are desperately short of doses.

J.P. Morgan Stick to Their Hold Rating for Novavax